Arbutus Biopharma Corporation develops infectious-disease therapeutics centered on chronic hepatitis B, including imdusiran (AB-729), a GalNAc-conjugated RNAi therapeutic, and AB-101, an oral PD-1 inhibitor. News for ABUS commonly covers clinical data, regulatory designations such as FDA Fast Track for imdusiran, scientific-meeting abstracts, and corporate updates tied to the company’s cHBV programs.
Recurring coverage also includes financial results, capital-allocation updates, licensing revenue from lipid nanoparticle technology, and intellectual-property developments involving Arbutus and its licensee Genevant Sciences. The company’s LNP delivery technology and related patent matters are a recurring business theme alongside its clinical-stage antiviral pipeline.
Arbutus Biopharma (ABUS) has accepted 46,000,000 common shares for purchase and cancellation following the final results of its modified Dutch auction tender offer. The purchase price is US$5.00 per share, totaling US$230 million excluding fees and expenses. Accepted shares represent approximately 23 percent of shares outstanding on September 29, 2026, when the offer expired.
The offer was oversubscribed: eligible auction and purchase-price tenders had approximately 55.6% accepted, except odd lots. Tenders above US$5.00 were not purchased. A separate, unprorated proportionate-tender pool accounted for 9,307,231 accepted shares. Roivant Sciences will maintain approximately 19.5% ownership after completion. Arbutus anticipates approximately 153,275,907 shares outstanding immediately after completion. The depositary will effect payment and settlement on or about October 5, 2026.
Arbutus Biopharma (ABUS) announced preliminary tender-offer results and expects to purchase common shares for cancellation totaling US$230 million. The offer expired September 29, 2026. The expected purchase is 46,000,000 shares at US$5.00 each, excluding fees and expenses, representing approximately 23 percent of shares outstanding that day. Arbutus anticipates approximately 153,275,907 shares outstanding after completion.
The offer was oversubscribed, with 65,907,215 shares tendered through eligible auction and purchase-price tenders. Arbutus expects approximately 55 percent of those tendered shares to be purchased, except odd lots, which avoid proration. Another 9,307,231 shares are anticipated to be purchased through proportionate tenders. Roivant will maintain approximately 19.5% ownership. Results remain preliminary, subject to depositary verification and timely delivery of shares tendered through guaranteed delivery.
Arbutus Biopharma (Nasdaq: ABUS) has launched a modified “Dutch Auction” tender offer to repurchase for cancellation up to US$230 million of its common shares at prices between US$5.00 and US$5.75 per share, payable in cash and funded from existing cash on hand.
The offer began on August 24, 2026 and is scheduled to expire at 5:00 p.m. New York City time on September 29, 2026, unless extended or terminated. If fully subscribed, the buyback would represent approximately 20.2%–23.2% of the 198,105,743 shares outstanding as of August 19, 2026, depending on the final purchase price.
Shareholders may tender via auction tenders, purchase price tenders or proportionate tenders. Odd lot holders who tender all their shares receive preferential acceptance. Arbutus has obtained exemptive relief in Canada and from the SEC for certain proportionate tender mechanics.
Arbutus Biopharma (Nasdaq: ABUS) plans to launch a modified “Dutch Auction” tender offer to repurchase up to US$230 million of its common shares. The proposed cash offer would be at prices between US$5.00 and US$5.75 per share, funded from cash on hand.
The offer is expected to begin on or about August 24, 2026 and expire on or about September 29, 2026, unless extended or terminated. Commencement is conditional on Arbutus obtaining specified exemptive relief in Canada and the United States. J.P. Morgan Securities will act as dealer-manager, with Georgeson as information agent and TSX Trust as depositary.
Arbutus Biopharma (Nasdaq: ABUS) reported second quarter 2026 results, highlighting a strong balance sheet with $92.6M in cash, cash equivalents and marketable securities as of June 30, 2026 and a $179.4M receivable from a Genevant license. In July 2026, Arbutus received $178.4M as its share of a previously announced $950M noncontingent settlement payment from Moderna and plans to return up to approximately $230M of capital to shareholders, potentially beginning in Q3 2026 via various share repurchase mechanisms, subject to board approval.
Imdusiran (AB-729) received FDA Fast Track designation in April 2026, and in May 2026 Arbutus reached alignment with the FDA on a proposed Phase 2b trial design in chronic hepatitis B. Q2 2026 revenue was $1.0M versus $10.7M a year earlier, with a net loss of $5.1M compared to net income of $2.5M in Q2 2025.
Summary not available.
Summary not available.
Summary not available.
Arbutus (Nasdaq: ABUS) reported Q4 and full-year 2025 results and a corporate update on March 23, 2026. Key highlights include $91.5M in cash and marketable securities, a $2.25B global settlement with Moderna (noncontingent $950M plus $1.3B contingent), and two additional imdusiran patients achieving functional cure, totaling 10 to date.
2025 revenue was $14.1M, net loss $33.5M, and 192.5M shares outstanding. The company plans to evaluate a return of capital in Q3 2026 following receipt of settlement proceeds.
Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences announced a $2.25 billion global settlement with Moderna on March 3, 2026. Moderna will pay $950 million upfront in July 2026 and a $1.3 billion contingent payment tied to an appellate ruling on Section 1498. The settlement includes a court judgment of infringement and no invalidity on four patents and grants Moderna a global non-exclusive license to LNP delivery technology for infectious-disease mRNA vaccines.
Arbutus is evaluating a return of capital to shareholders in Q3 2026 in conjunction with the upfront payment.